Popular Type 2 diabetes medicine Mounjaro released in India

Mounjaro (tirzepatide), a breakthrough drug for the treatment of Type 2 diabetes and obesity, has been released in India. The drug has been approved by the Central Drugs Standard Control Organization (CDSCO).

Endocrinologists hail Mounjaro as transformative for India’s dual diabetes-obesity crisis. However, affordability limits accessibility, with annual costs reaching Rs 700,000 for high doses. Local pharma firms like Sun Pharma and Cipla are advancing generic GLP-1 analogs, potentially disrupting the market post-2026 semaglutide patent expiry.

Introduction and Approval

Eli Lilly launched Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, in India on March 20, 2025, after securing approval from the Central Drugs Standard Control Organisation (CDSCO). The drug is indicated for obesity (BMI ≥30), overweight individuals with comorbidities (BMI ≥27), and type 2 diabetes. This marks a strategic entry into a market with 101 million diabetics and 100 million obese adults, addressing a critical public health gap.

Pricing and Accessibility

Mounjaro is priced at Rs 3,500 (2.5 mg vial) and Rs 4,375 (5 mg vial), translating to monthly costs of Rs 14,000– Rs 17,500. While significantly cheaper than U.S. prices ($1,086/month), analysts note this remains costly for most Indians. Eli Lilly positions it as a premium option ahead of Novo Nordisk’s Wegovy, expected in 2026.

Safety Profile and Contraindications

Common side effects include nausea (20–30%), diarrhea (12–18%), and constipation (10–15%). Black box warnings highlight risks of thyroid tumors and pancreatitis. Contraindicated for patients with MEN2 syndrome or prior pancreatitis, it requires refrigeration (2–8°C) and subcutaneous administration training.